---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-21-000039"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2021-08-12T23:59:59+00:00"
generated_at: "2026-06-29T13:37:15.540927+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics reports Q2 2021 net loss $10.9M; cash of $183.2M after IPO

## Summary
- Completed May 2021 IPO: 7.5M shares at $16.00, net proceeds $109.2M.
- Cash and cash equivalents $183.2M at June 30, 2021, up from $92.6M at Dec 31, 2020.
- Q2 2021 net loss $10.9M vs $2.3M Q2 2020; R&D expenses $7.3M vs $3.8M.
- Appointed Chulani Karunatilake as CTO and Mike Sherman to Board of Directors.
- Existing cash expected to fund operations through at least Q2 2023.

## SEC filing metadata
- accession: 0001785530-21-000039
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2021-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553021000039/0001785530-21-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553021000039/howl-20210812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-21-000039
- JSON: https://secwatch.observer/filing/0001785530-21-000039.json
- Plain text: https://secwatch.observer/filing/0001785530-21-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.